DK1401869T3 - Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1 - Google Patents

Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1

Info

Publication number
DK1401869T3
DK1401869T3 DK02734634T DK02734634T DK1401869T3 DK 1401869 T3 DK1401869 T3 DK 1401869T3 DK 02734634 T DK02734634 T DK 02734634T DK 02734634 T DK02734634 T DK 02734634T DK 1401869 T3 DK1401869 T3 DK 1401869T3
Authority
DK
Denmark
Prior art keywords
methods
excretion
molecules
inhibiting germ
kim
Prior art date
Application number
DK02734634T
Other languages
Danish (da)
English (en)
Inventor
Veronique Bailly
Joseph Bonventre
Original Assignee
Biogen Idec Inc
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Gen Hospital Corp filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1401869T3 publication Critical patent/DK1401869T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02734634T 2001-06-01 2002-05-31 Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1 DK1401869T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29544901P 2001-06-01 2001-06-01
US29590701P 2001-06-04 2001-06-04
PCT/US2002/017402 WO2002098920A1 (en) 2001-06-01 2002-05-31 Molecules and methods for inhibiting shedding of kim-1

Publications (1)

Publication Number Publication Date
DK1401869T3 true DK1401869T3 (da) 2008-04-28

Family

ID=26969139

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02734634T DK1401869T3 (da) 2001-06-01 2002-05-31 Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1

Country Status (10)

Country Link
US (3) US7041290B2 (enExample)
EP (1) EP1401869B1 (enExample)
JP (2) JP4527394B2 (enExample)
AT (1) ATE382060T1 (enExample)
AU (1) AU2002305785B2 (enExample)
CA (1) CA2448427C (enExample)
DE (1) DE60224275T2 (enExample)
DK (1) DK1401869T3 (enExample)
NZ (1) NZ530457A (enExample)
WO (1) WO2002098920A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2258793T5 (es) * 1996-05-24 2010-01-25 Biogen Idec Ma Inc. Moduladores de la regeneracion tisular.
ATE425249T1 (de) * 2000-06-16 2009-03-15 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
AU2003228336B2 (en) * 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2013205381B2 (en) * 2002-03-19 2016-04-14 Celldex Therapeutics, Inc. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP2025345A1 (en) * 2002-12-30 2009-02-18 Biogen Idec MA Inc. KIM-1 antagonists and use to modulate immune system
WO2004084823A2 (en) * 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
AU2013242840B2 (en) * 2003-03-19 2017-01-19 Amgen Fremont Inc. Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof
EP1532984A1 (en) * 2003-11-19 2005-05-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia
KR101213894B1 (ko) * 2005-03-02 2012-12-20 바이오겐 아이덱 엠에이 인코포레이티드 Ｔｈ2 매개성 병태를 치료하기 위한 ｋｉｍ-1 항체
EP1957115B8 (en) 2005-11-10 2014-03-05 Celldex Therapeutics, Inc. Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
EP2517020B1 (en) 2009-12-23 2015-10-21 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating kidney disorders in a canine
SG182408A1 (en) 2010-01-11 2012-08-30 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
MX340696B (es) 2010-04-30 2016-07-21 Alexion Pharma Inc Anticuerpos anti-c5a y metodos para usar los anticuerpos.
WO2012106634A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
WO2013078089A1 (en) * 2011-11-22 2013-05-30 Biogen Idec Ma Inc. Anti-tim-1 antibodies and uses thereof
WO2015023836A1 (en) * 2013-08-16 2015-02-19 The Brigham And Women's Hospital, Inc. Kim-1 as a therapeutic target in conditions associated with kidney fibrosis
US10712349B2 (en) 2014-04-15 2020-07-14 The Brigham And Women's Hospital, Inc. Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
EP3568416A4 (en) * 2017-01-13 2020-07-08 Celdara Medical, LLC TIM-1 TARGETED CHIMERIC ANTIGENIC RECEPTORS
CN110799492B (zh) 2017-04-28 2023-06-27 爱康泰生治疗公司 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
IL281615B2 (en) 2018-09-21 2026-01-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
PT3908568T (pt) 2019-01-11 2024-09-30 Acuitas Therapeutics Inc Lípidos para a administração de agentes ativos por nanopartículas lipídicas
ES3054438T3 (en) 2020-07-16 2026-02-03 Acuitas Therapeutics Inc Cationic lipids for use in lipid nanoparticles
CA3242402A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622861A (en) 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
ES2258793T5 (es) 1996-05-24 2010-01-25 Biogen Idec Ma Inc. Moduladores de la regeneracion tisular.
ATE425249T1 (de) * 2000-06-16 2009-03-15 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
US7553939B2 (en) 2001-06-29 2009-06-30 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes and methods of use thereof
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
AU2002330039A1 (en) 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
US7470428B2 (en) 2002-01-30 2008-12-30 The Brigham And Women's Hospital, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
AU2003228336B2 (en) 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
WO2004084823A2 (en) 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
US20050119210A1 (en) 2003-05-20 2005-06-02 Xiaobing Be Compositions and methods for diagnosing and treating cancers

Also Published As

Publication number Publication date
JP2005505256A (ja) 2005-02-24
US20080124336A1 (en) 2008-05-29
JP4527394B2 (ja) 2010-08-18
EP1401869A4 (en) 2005-10-19
US20050112117A1 (en) 2005-05-26
CA2448427A1 (en) 2002-12-12
EP1401869A1 (en) 2004-03-31
JP2010150291A (ja) 2010-07-08
WO2002098920A1 (en) 2002-12-12
DE60224275T2 (de) 2008-12-11
US7300652B2 (en) 2007-11-27
US7041290B2 (en) 2006-05-09
US20060153836A1 (en) 2006-07-13
ATE382060T1 (de) 2008-01-15
CA2448427C (en) 2013-09-24
AU2002305785B2 (en) 2008-01-17
EP1401869B1 (en) 2007-12-26
NZ530457A (en) 2007-12-21
US7696321B2 (en) 2010-04-13
DE60224275D1 (de) 2008-02-07

Similar Documents

Publication Publication Date Title
DK1401869T3 (da) Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
DK1171417T3 (da) Fremgangsmåde til fremstilling af 3-aryloxy-3-arylpropylaminer og mellemprodukter deraf
TR200602095T2 (tr) Hümanize Anti-LT-Beta-R antikorları
NO20030856D0 (no) Membranpenetrerende peptider og anvendelse av disse
DK2258168T3 (da) Apparat til isolering af X-kromosombærende og Y-kromosombærende populationer af spermatozoer
DK2322603T3 (da) Sammensætninger og fremgangsmåder til aktivering af monocytiske dendritiske celler og t-celler for th1-respons
DK1066049T3 (da) Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse
DE60220529D1 (de) Quantisiertes förderungssystem für 'solid free form fabrication'
ITRM20030376A1 (it) Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
DK0833839T3 (da) Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme
DK1352895T3 (da) Adamantanderivater til behandling af inflammatioriske immunologiske og kardiovaskulære sygdomme
DK1437966T3 (da) Måling af proteinsyntesehastigheder hos mennesker og i forsøgssystemer ved anvendelse af isotopisk mærket vand
DE50002884D1 (de) Fitting-anlage
DE60137015D1 (de) Verdichteranlage
DK1184474T3 (da) Fremgangsmåde til fremstilling af meget tynde bånd i aluminium-jern-legering
MA30265B1 (fr) Procedes et compositions destines a cibler relt
DE50106206D1 (de) Turbinenanlage
DK1484056T3 (da) Sammensætninger med langsom frigivelse og fremgangsmåde til fremstilling af disse
ATE298471T1 (de) Zweidimensionale pyramidenfilterarchitektur
DE60139893D1 (de) Neue fructosyl-aminosäureoxidase
DK1316239T3 (da) Höreapparat og fremgangsmåde til fremstilling af samme
DK1318142T3 (da) t-butoxycarbonylaminoethylamin til syntese af PNA-monomerenheder, aminosyrederivater, mellemprodukter deraf og fremgangsmåder til fremstilling af disse
LU90968B1 (de) Schlackengranulierungsanlage
DK1194158T3 (da) Anvendelse af UK 114-proteiner til hæmning af organtransplantatafstödning
ATE287590T1 (de) Zweidimensionale pyramidenfilterarchitektur